PON1 activity and total oxidant status in patients with active pulmonary tuberculosis

Clinical Biochemistry

Volumn 41, Issue 3, 2008, Pages 140-144

  Selek, Sahbettin ^a   Cosar, Niyet ^a   Kocyigit, Abdurrahim ^a   Erel, Ozcan ^a   Aksoy, Nurten ^a   Gencer, Mehmet ^a   Gunak, Faruk ^a   Aslan, Mehmet ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Active pulmonary tuberculosis; Atherosclerosis; PON1 activity; Total SH; Total oxidant status

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID HYDROPEROXIDE; OXIDIZING AGENT; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SOCIAL ASPECT;

ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; FEMALE; HUMANS; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REFERENCE VALUES; SULFHYDRYL COMPOUNDS; TUBERCULOSIS, PULMONARY;

EID: 38649094585     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.11.018     Document Type: Article

References (36)

1. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
2. Kwiatkowska S., Szkudlarek U., Luczynska M., Nowak D., and Zieba M. Elevated exhalation of hydrogen peroxide and circulating IL-18 in patients with pulmonary tuberculosis. Respir Med 101 (2007) 574-580
3. Kocyigit A., Keles H., Selek S., Guzel S., Celik H., and Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutat Res 585 (2005) 71-78
4. Shamir R., Hartman C., Karry R., et al. Paraoxonases (PONs) 1, 2 and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic Biol Med 39 (2005) 336-344
5. Fuhrman B., Volkova N., and Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 180 (2005) 55-61
6. Deakin S., Moren X., and James R.W. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 179 (2005) 17-25
7. Rosenblat M., Karry R., and Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 187 (2006) 74.el-74.e10
8. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101 (2000) 2510-2517
9. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
10. Mackness M.I., Arrol S., Abbott C., and Durington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
11. Mackness B., Mackness M.I., Durington P.N., et al. Paraoxonase activity in two healthy population with differing rates of coronary heart disease. Eur J Clin Invest 30 (2000) 4-10
12. McElven J., Mackness M.I., Collley C.M., et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32 (1986) 671-673
13. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., and Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34 (2003) 774-784
14. Kiechl S., Egger G., Mayr M., et al. Chronic infections and the risk of carotid atherosclerosis prospective results from a large population study. Circulation 103 (2001) 1064-1070
15. George J., Shoenfeld Y., Gilburd B., Afek A., Shaish A., and Harats D. Requisite role for interleukin-4 the in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res 86 (2000) 1203-1210
16. Rota S., and Rota S. Mycobacterium tuberculosis complex in atherosclerosis. Acta Med Okayama 59 (2005) 247-251
17. Seres I., Pragh G., Deschene, Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp gerontol 39 (2004) 59-66
18. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paroxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
19. Erel O. Anew automated colorimetric method for measuring total oxidant status. Clin Biochem 38 (2005) 1103-1111
20. Arab K., and Steghnes J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 325 (2004) 158-163
21. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37 (2004) 112-119
22. Wiid I., Seaman T., Hoal E.G., Benade A.J., and Van Helden P.D. Total antioxidant levels are low during active TB and rise with anti-tuberculosis therapy. IUBMB Life 56 2 (2004) 101-106
23. Chan J., Tanaka K., Carroll D., Flynn J., and Bloom B.R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 63 (1995) 736-740
24. Serdar Z., Aslan K., Dirican M., Sarandol E., Yesilbursa D., and Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 39 (2006) 794-803
25. Aviram M., Rosenblat M., Billecke S., Eroglu J., Sorenson S., and Bisgaier C.L. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
26. Aviram M., and Rosenblat M. Paraoxonases 1,2, and 3, oxidative stress and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37 (2004) 1304-1316
27. Mackness B., Durington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the caterphilly prospective study. Circulation 107 (2003) 2775-2779
28. Witzum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
29. Esterbauer H., Wag G., and Puhl H. Lipid peroxidation and its role in atherosclerosis. Br Med Bull 49 (1993) 566-576
30. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
31. Paragh G., Seres I., Balogh Z., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998) 166-170
32. Rozenberg O., and Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 351 (2006) 492-498
33. Gur M., Aslan M., Yildiz A., et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 36 (2006) 779-787
34. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., and Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 191 (2007) 397-402
35. Serrato M., and Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96 (1995) 3005-3008
36. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76